Equities research analysts predict that Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) will post ($0.50) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Spring Bank Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.49). Spring Bank Pharmaceuticals reported earnings of ($0.47) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 6.4%. The business is scheduled to announce its next quarterly earnings report on Tuesday, February 19th.
According to Zacks, analysts expect that Spring Bank Pharmaceuticals will report full-year earnings of ($1.70) per share for the current fiscal year, with EPS estimates ranging from ($1.81) to ($1.53). For the next financial year, analysts anticipate that the business will post earnings of ($2.22) per share, with EPS estimates ranging from ($2.67) to ($1.90). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Spring Bank Pharmaceuticals.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last released its earnings results on Thursday, October 25th. The company reported ($0.51) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.01.
NASDAQ SBPH traded down $0.03 during trading hours on Friday, hitting $11.78. 22,900 shares of the company’s stock were exchanged, compared to its average volume of 48,129. Spring Bank Pharmaceuticals has a 12-month low of $8.88 and a 12-month high of $18.93. The company has a market capitalization of $190.96 million, a PE ratio of -6.30 and a beta of 0.89.
In other Spring Bank Pharmaceuticals news, insider Martin J. Driscoll bought 4,000 shares of Spring Bank Pharmaceuticals stock in a transaction that occurred on Monday, August 13th. The shares were purchased at an average cost of $12.02 per share, for a total transaction of $48,080.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 15.60% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. Jennison Associates LLC acquired a new stake in Spring Bank Pharmaceuticals during the third quarter worth about $8,210,000. BlackRock Inc. increased its stake in Spring Bank Pharmaceuticals by 1,498.8% during the second quarter. BlackRock Inc. now owns 483,258 shares of the company’s stock worth $5,727,000 after acquiring an additional 453,032 shares during the last quarter. Morse Asset Management Inc increased its stake in Spring Bank Pharmaceuticals by 7.1% during the third quarter. Morse Asset Management Inc now owns 190,050 shares of the company’s stock worth $2,290,000 after acquiring an additional 12,550 shares during the last quarter. Millennium Management LLC increased its stake in Spring Bank Pharmaceuticals by 82.3% during the first quarter. Millennium Management LLC now owns 91,663 shares of the company’s stock worth $1,410,000 after acquiring an additional 41,372 shares during the last quarter. Finally, C WorldWide Group Holding A S increased its stake in Spring Bank Pharmaceuticals by 4.9% during the second quarter. C WorldWide Group Holding A S now owns 91,567 shares of the company’s stock worth $1,085,000 after acquiring an additional 4,245 shares during the last quarter. Institutional investors own 27.11% of the company’s stock.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).
See Also: How Do I Invest in Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.